Optiscan has been featured in Stockhead’s ASX Quarterly Health Wrap, highlighting the company’s continued momentum across its regulatory, clinical and commercial programs during Q4 FY26 as it progresses towards planned US FDA submissions for its InVue and InForm platforms.

The article highlights progress across Optiscan’s clinical development program, including its breast cancer imaging study at The Royal Melbourne Hospital, which had completed 34 of 50 planned cases by 30 June, with a second site at Frances Perry House helping accelerate enrolment.

It also notes continued progress in the company’s head and neck cancer and anatomical pathology studies, preparations for two US-based Mayo Clinic studies, and ethics approval for its gastrointestinal imaging study with University Medical Centre Mainz in Germany.

On the commercial front, Stockhead highlights Optiscan’s go-to-market planning across InSpecta, InVue and InForm, alongside the subsequent US launch of InSpecta at the American Veterinary Medical Association Convention.

CEO and Managing Director Dr. Camile Farah said: “As we enter FY27, Optiscan is continuing to enjoy clear-cut development momentum with another round of commercial and regulatory milestones set to soon be realised.”

Stockhead – Read the full article here.